SLC29A1 and neoplasm: The nano-carrier approach based on the kinds of nanoparticle has been reported as a promising measure, although its clinical application value is still under study, to reduce the dependence on hENT1 and enhance the permeability of gemcitabine, thereby increasing the concentration of gemcitabine in tumour cells, which has been demonstrated in vitro and in vivo [38,39].